Sagimet Biosciences (SGMT) Total Liabilities (2022 - 2026)

Sagimet Biosciences' Total Liabilities history runs 5 years deep, the most recent figure standing at $107.8 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 1400.77% year-over-year to $107.8 million in Q1 2026; TTM through Mar 2026 was $107.8 million, a 1400.77% increase from a year earlier, with the FY2025 full-year figure at $116.5 million, up 2515.22% from the prior year.
• Total Liabilities slipped to $107.8 million in Q1 2026 per SGMT's latest filing, from $116.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $137.4 million in Q2 2025 and bottomed at $4.1 million in Q3 2024.
• The 5-year median for Total Liabilities is $5.7 million (2023), against an average of $41.3 million.
• Across the five-year window, Total Liabilities decreased 21.22% in 2024 and soared 3037.85% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $5.4 million in 2022, then gained by 5.47% to $5.7 million in 2023, then dropped by 21.22% to $4.5 million in 2024, then surged by 2515.22% to $116.5 million in 2025, then retreated by 7.49% to $107.8 million in 2026.
• Per Business Quant, the three latest SGMT Total Liabilities figures stand at $107.8 million (Q1 2026), $116.5 million (Q4 2025), and $128.4 million (Q3 2025).